stockrow
Friday 6 November 2026
Export DFTX’s income statement to Excel — free account
Definium Therapeutics, Inc.
DFTX Healthcare Biotechnology
- EPS
- −188.0%
- Free cash flow
- −78.3%
- Total debt
- −11.5%
Quarter to June 2026, against a year earlier
33.27
2.91
+9.58%
Follow DFTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 29 | 29 | 271 | +203.9% | |
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | 0 | (1) | (1) | (11) | (34) | (94) | (57) | (96) | (109) | (184) | (354) | +123.3% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | 0 | 0 | (1) | (11) | (34) | (93) | (57) | (96) | (109) | (184) | (354) | +123.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.09) | — | (2.02) | (1.56) | (1.91) | (3.45) | (1.84) | (2.44) | (1.54) | (2.06) | (3.43) | +41.8% | ||||||
| Cash flow | (0.02) | (2.11) | (1.70) | (0.47) | (1.33) | (1.67) | (1.62) | (1.64) | (1.12) | (1.47) | (1.52) | +64.9% | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (0.02) | (2.11) | (1.70) | (0.47) | (1.33) | (1.67) | (1.62) | (1.64) | (1.12) | (1.47) | (1.52) | +64.9% | ||||||
| Book value | 0.08 | 12.49 | 8.29 | 0.00 | 4.27 | 5.54 | 4.89 | 2.00 | 3.43 | 3.72 | 8.30 | +53.6% | ||||||
| Shares, m | 1 | 0 | 0 | 7 | 18 | 27 | 31 | 39 | 70 | 89 | 99 | +61.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | (1) | (1) | (3) | (24) | (46) | (50) | (64) | (79) | (132) | (168) | +166.0% | |||||
| Capex | 0 | (2) | (1) | 0 | — | — | — | — | — | — | 0 | +121.2% | ||||||
| Free cash flow | 0 | (1) | (1) | (3) | (24) | (46) | (50) | (64) | (79) | (132) | (168) | +166.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | 1 | 0 | 2 | 79 | 127 | 128 | 72 | 243 | 353 | 935 | +170.8% | |||||
| Net debt | 0 | (1) | 0 | 0 | (80) | (134) | (142) | (86) | (252) | (371) | (1,047) | +150.4% | ||||||
| Shareholders’ equity | 0 | 3 | 3 | — | 76 | 152 | 151 | 78 | 241 | 332 | 919 | +147.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (7.90) | (1,306.54) | (45.91) | (823.70) | (80.69) | (75.79) | (34.01) | (65.01) | (50.94) | (49.52) | (51.35) | (41.6) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (323.63) | (472.44) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (8.20) | (60.35) | (21.94) | (455.48) | (87.05) | (81.78) | (37.54) | (83.59) | (68.01) | (64.06) | (64.09) | (55.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 41 | 48 | 57 | 74 | 106 | — | +26.8% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Definium Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics, Inc. | $4.6B | — (loss-making) | — (loss-making) | +205.56% (above 0%: growing) | n/m | −65.91% (below 0%: shrinking) | 100.00% | (4,832.40%) | Compare |
| ERAS Erasca, Inc. | $4.6B | — (loss-making) | — | — | n/m | −4.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LEGN Legend Biotech Corporation Sponsored ADR | $4.4B | — (loss-making) | — (loss-making) | +51.90% (above 0%: growing) | n/m | −26.79% (below 0%: shrinking) | 64.54% | 14.37% | Compare |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | 4.9× | — | — | n/m | −30.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DFTX Definium Therapeutics, Inc. | $4.1B | — (loss-making) | — | — | n/m | −78.31% (below 0%: shrinking) | 0.00% | 0.00% | |
| RLAY Relay Therapeutics, Inc. | $3.7B | — (loss-making) | — (loss-making) | −95.44% (below 0%: shrinking) | n/m | +2.13% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ACAD ACADIA Pharmaceuticals Inc. | $3.7B | 10.0× | 33.4× | +22.85% (above 0%: growing) | −27.86% (below 0%: shrinking) | +141.15% (above 0%: growing) | 89.75% | 20.95% | Compare |
| XENE Xenon Pharmaceuticals Inc. | $3.7B | — (loss-making) | — (loss-making) | +100.70% (above 0%: growing) | n/m | −48.57% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ABCL AbCellera Biologics Inc. | $3.6B | — (loss-making) | — (loss-making) | −76.29% (below 0%: shrinking) | n/m | +151.98% (above 0%: growing) | 100.00% | (1,550.05%) | Compare |
| Median of peers | $4.0B | — | — | +37.38% | — | −15.73% | 94.88% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Ownership
Directors and executive officers, together
2.40%
Commodore Capital LP
6.80%
Driehaus Capital Management LLC
6.00%
BlackRock,Inc.
5.60%
Deep Track Capital, LP
5.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement